DGAP-News: Heidelberg Pharma AG
/ Key word(s): Conference
06.11.2019 / 10:41
The issuer is solely responsible for the content of this announcement.
Heidelberg Pharma Announces Participation at Various Conferences
Ladenburg, Germany, 6 November 2019 – Heidelberg Pharma AG (FSE: WL6) today announced that they will participate at the following investor events and scientific conferences. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology, and to advance the biological mode of action of the toxin as a novel therapeutic principle.
10th Jefferies 2019 London Healthcare Conference
German Equity Forum 2019
Dr. Jan Schmidt-Brand, Chief Executive Officer and Chief Financial Officer of Heidelberg Pharma, will give a company presentation on Monday, 25 November 2019 at 02:30 pm CET in room Oslo.
PEGS Europe: The Essential Protein Engineering Summit
Dr. George Badescu, Vice President Scientific Affairs of Heidelberg Pharma, will give the following presentation on Monday, 18 November 2019 at 02:45 pm UTC (03:45 pm CET):
Amanitin-Based Antibody-Drug Conjugates as New Therapeutic Modalities for Cancer Therapy
Information on the conference: https://www.pegsummiteurope.com
Furthermore, Heidelberg Pharma will publish research results of the MAGICBULLET project in a poster presentation.
Details of the presentation:
A New Small-Molecule-Drug-Conjugate Platform for Targeted Tumor Therapy: α-Amanitin-based Drug Conjugates Targeting PSMA
About Heidelberg Pharma’s proprietary ATAC technology
About Heidelberg Pharma
The Company has entered into partnerships to further develop and commercialize its clinical assets MESUPRON(R) and REDECTANE(R). Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at www.heidelberg-pharma.com.
This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will” “should” “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.
06.11.2019 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Company:||Heidelberg Pharma AG|
|Schriesheimer Str. 101|
|Phone:||+49 (0)89 41 31 38 – 0|
|Fax:||+49 (0)89 41 31 38 – 99|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||905793|
|End of News||DGAP News Service|